246 related articles for article (PubMed ID: 23583511)
1. Design considerations for PAMAM dendrimer therapeutics.
Goonewardena SN; Kratz JD; Zong H; Desai AM; Tang S; Emery S; Baker JR; Huang B
Bioorg Med Chem Lett; 2013 May; 23(10):2872-5. PubMed ID: 23583511
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio.
Zong H; Thomas TP; Lee KH; Desai AM; Li MH; Kotlyar A; Zhang Y; Leroueil PR; Gam JJ; Banaszak Holl MM; Baker JR
Biomacromolecules; 2012 Apr; 13(4):982-91. PubMed ID: 22360561
[TBL] [Abstract][Full Text] [Related]
3. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality.
Majoros IJ; Myc A; Thomas T; Mehta CB; Baker JR
Biomacromolecules; 2006 Feb; 7(2):572-9. PubMed ID: 16471932
[TBL] [Abstract][Full Text] [Related]
4. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
5. Targeting and inhibition of cell growth by an engineered dendritic nanodevice.
Thomas TP; Majoros IJ; Kotlyar A; Kukowska-Latallo JF; Bielinska A; Myc A; Baker JR
J Med Chem; 2005 Jun; 48(11):3729-35. PubMed ID: 15916424
[TBL] [Abstract][Full Text] [Related]
6. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
7. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Patri AK; Kukowska-Latallo JF; Baker JR
Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
[TBL] [Abstract][Full Text] [Related]
8. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
[TBL] [Abstract][Full Text] [Related]
9. Targeted dendrimeric anticancer prodrug: a methotrexate-folic acid-poly(amidoamine) conjugate and a novel, rapid, "one pot" synthetic approach.
Zhang Y; Thomas TP; Desai A; Zong H; Leroueil PR; Majoros IJ; Baker JR
Bioconjug Chem; 2010 Mar; 21(3):489-95. PubMed ID: 20128612
[TBL] [Abstract][Full Text] [Related]
10. Folate-functionalized unimolecular micelles based on a degradable amphiphilic dendrimer-like star polymer for cancer cell-targeted drug delivery.
Cao W; Zhou J; Mann A; Wang Y; Zhu L
Biomacromolecules; 2011 Jul; 12(7):2697-707. PubMed ID: 21619062
[TBL] [Abstract][Full Text] [Related]
11. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates.
Myc A; Douce TB; Ahuja N; Kotlyar A; Kukowska-Latallo J; Thomas TP; Baker JR
Anticancer Drugs; 2008 Feb; 19(2):143-9. PubMed ID: 18176110
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiproliferative activity of novel steroidal dendrimer conjugates.
Magaña-Vergara NE; Rárová L; Soto-Castro D; Farfán N; Strnad M; Santillan R
Steroids; 2013 Dec; 78(12-13):1254-62. PubMed ID: 24060952
[TBL] [Abstract][Full Text] [Related]
14. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic.
Thomas TP; Huang B; Choi SK; Silpe JE; Kotlyar A; Desai AM; Zong H; Gam J; Joice M; Baker JR
Mol Pharm; 2012 Sep; 9(9):2669-2676. PubMed ID: 22827500
[TBL] [Abstract][Full Text] [Related]
15. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
16. Cellular uptake of glucoheptoamidated poly(amidoamine) PAMAM G3 dendrimer with amide-conjugated biotin, a potential carrier of anticancer drugs.
Uram Ł; Szuster M; Filipowicz A; Zaręba M; Wałajtys-Rode E; Wołowiec S
Bioorg Med Chem; 2017 Jan; 25(2):706-713. PubMed ID: 27919613
[TBL] [Abstract][Full Text] [Related]
17. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
18. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells.
Yue Y; Eun JS; Lee MK; Seo SY
Arch Pharm Res; 2012 Feb; 35(2):343-9. PubMed ID: 22370789
[TBL] [Abstract][Full Text] [Related]
20. Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes.
Muñoz AM; Fragoso-Vázquez MJ; Martel BP; Chávez-Blanco A; Dueñas-González A; R García-Sánchez J; Bello M; Romero-Castro A; Correa-Basurto J
Anticancer Agents Med Chem; 2020; 20(15):1857-1872. PubMed ID: 32324521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
